Fox Chase Researchers Report that a Less Toxic Combination of Erlotinib and Bevacizumab is Effective and Well-Tolerated in Non-Small Cell Lung Cancer Patients
CHICAGO, IL (June 4, 2011) — The standard treatment for patients with advanced non-small cell lung cancer (NSCLC) is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity. Now, Fox Chase Cancer Center researchers report that a combination of two molecularly-targeted agents may provide similar therapeutic benefit with less toxicity.